AFFIMED NV (AFMD)
NL0015001ZQ0 - Common Stock
We assign a fundamental rating of 2 out of 10 to AFMD. AFMD was compared to 565 industry peers in the Biotechnology industry. AFMD has a bad profitability rating. Also its financial health evaluation is rather negative. AFMD is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AFMD has reported negative net income.
In the past year AFMD has reported a negative cash flow from operations.
AFMD had negative earnings in each of the past 5 years.
AFMD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -175.10%, AFMD is not doing good in the industry: 88.59% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -406.92%, AFMD is doing worse than 77.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -175.1% | ||
| ROE | -406.92% | ||
| ROIC | N/A |
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AFMD has a Gross Margin of 789.74%. This is amongst the best in the industry. AFMD outperforms 100.00% of its industry peers.
AFMD's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AFMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 789.74% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
2. Health
2.1 Basic Checks
AFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
AFMD has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for AFMD has been increased compared to 5 years ago.
AFMD has a worse debt/assets ratio than last year.
2.2 Solvency
AFMD has an Altman-Z score of -3.38. This is a bad value and indicates that AFMD is not financially healthy and even has some risk of bankruptcy.
AFMD has a Altman-Z score of -3.38. This is comparable to the rest of the industry: AFMD outperforms 47.24% of its industry peers.
A Debt/Equity ratio of 0.35 indicates that AFMD is not too dependend on debt financing.
AFMD has a worse Debt to Equity ratio (0.35) than 71.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.38 |
ROIC/WACCN/A
WACC6.73%
2.3 Liquidity
AFMD has a Current Ratio of 1.93. This is a normal value and indicates that AFMD is financially healthy and should not expect problems in meeting its short term obligations.
AFMD has a worse Current ratio (1.93) than 76.65% of its industry peers.
A Quick Ratio of 1.93 indicates that AFMD should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.93, AFMD is doing worse than 75.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 41.65% over the past year.
AFMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.39%.
AFMD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -19.00% yearly.
EPS 1Y (TTM)41.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.75%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-91.76%
3.2 Future
The Earnings Per Share is expected to grow by 10.50% on average over the next years. This is quite good.
The Revenue is expected to grow by 62.72% on average over the next years. This is a very strong growth
EPS Next Y43.08%
EPS Next 2Y28.33%
EPS Next 3Y16.64%
EPS Next 5Y10.5%
Revenue Next Year-57.56%
Revenue Next 2Y-20.48%
Revenue Next 3Y-52.77%
Revenue Next 5Y62.72%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AFMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AFMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as AFMD's earnings are expected to grow with 16.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.33%
EPS Next 3Y16.64%
5. Dividend
5.1 Amount
AFMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AFFIMED NV
NASDAQ:AFMD (11/20/2024, 8:05:33 PM)
Premarket: 2.7 -0.02 (-0.74%)2.72
-0.28 (-9.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap41.43M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -175.1% | ||
| ROE | -406.92% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 789.74% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)41.65%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y43.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y